STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, has made available the replay of its Nasdaq Closing Bell Ceremony from August 8, 2025. The ceremony celebrated a significant milestone: the FDA 510(k) clearance for the company's new Daxor BVA™ (Blood Volume Analyzer).

The next-generation device is characterized as a patent-pending, rapid, compact, and hand-held blood volume measurement system designed for lab-based use.

Loading...
Loading translation...

Positive

  • Received FDA 510(k) clearance for next-generation Daxor BVA™
  • Successfully developed a compact, hand-held version of their blood volume measurement technology

Negative

  • None.

The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA.

Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA (Blood Volume Analyzer).

You can watch the full replay of the event here: Closing Ceremony.

For more information, visit daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com


FAQ

What milestone did Daxor (NASDAQ: DXR) celebrate at the Nasdaq Closing Bell Ceremony?

Daxor celebrated receiving FDA 510(k) clearance for its next-generation, patent-pending Daxor BVA™ (Blood Volume Analyzer).

When did Daxor (DXR) ring the Nasdaq Closing Bell?

Daxor rang the Nasdaq Closing Bell on August 8, 2025, with the replay being made available on August 12, 2025.

What are the key features of Daxor's new Blood Volume Analyzer?

The new Daxor BVA™ is a patent-pending, rapid, compact, and hand-held lab-based blood volume measurement device.

Where can investors watch Daxor's Nasdaq Closing Bell Ceremony?

The replay of Daxor's Nasdaq Closing Bell Ceremony is available through a link on the company's website at daxor.com.
DAXOR CORP

NASDAQ:DXR

DXR Rankings

DXR Latest News

DXR Latest SEC Filings

DXR Stock Data

64.80M
2.16M
56.64%
2.01%
0.77%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK